Leukocyte Differential on Hematology Analyzer Compared and Evaluated
|
By LabMedica International staff writers Posted on 21 Jun 2021 |

Image: The Celltac G fully-automatic hematology analyzer with 33 parameters (Photo courtesy of Nihon Kohden)
A complete blood count (CBC), also known as a full blood count (FBC), is a set of medical laboratory tests that provide information about the cells in a person's blood. The CBC indicates the counts of white blood cells, red blood cells and platelets, the concentration of hemoglobin, and the hematocrit (the volume percentage of red blood cells).
Different hematology analyzer models use various principles to measure the complete blood count (CBC) and leukocyte differential for routine tests in clinical laboratories. The accuracy performance of a hematology analyzer is evaluated using the manual differential leukocyte (Manual-Diff) on blood wedge film (Wedge-Diff) as the traditional reference method.
Clinical Laboratorians at the Kindai University Hospital (Osakasayama, Japan) selected for method comparison, 598 clinical samples and 46 healthy volunteer samples. All samples were collected in tubes containing K2-EDTA. The blood collection tubes, blood collection procedure, and mixing procedure were according to described methods. For method comparison between the three analyzers, 388 clinical samples were used. Blood films were stained with May-Giemsa.
The automated hematology analyzer Celltac G (Nihon Kohden, Tokyo, Japan) was designed to improve leukocyte differential performance. The two comparative hematology analyzers (CAAs) used were XN-9000 (Sysmex, Kobe, Japan) and CELL-DYN Sapphire (Abbott Diagnostics, Santa Clara, CA, USA). In manual differential, two kinds of automated slide makers were used: the Sysmex SP-10 for wedge technique and SPINNER-2000 (Lion-Power, Komatsu, Japan) for spinner technique. The immunophenotypic leukocyte differential reference method (FCM-Ref) was selected, and a flow cytometer Navios (Beckman-Coulter, Indianapolis, IN, USA) was used.
The investigators reported that the Celltac G showed sufficient comparability with the CAAs for each leukocyte differential counting value up to 40.87 × 109/L, and sufficient comparability with FCM-Ref for each leukocyte differential percentage at 0.4–78.5. The identification ratio of the FCM-Ref in CD45-positive cells was 99.7% (99.4% to 99.8%). Differences were found between FCM-Ref/Celltac G/XN-9000/Spinner-Diff and Wedge-Diff for monocytes and neutrophils. The appearance ratio of smudge cells on wedge and spinner film was 12.5% and 0.5%.
The authors concluded that the Celltac G hematology analyzer's leukocyte differential showed adequate accuracy compared with two comparative hematology analyzers, reference flow cytometry method, and two manual methods and was considered suitable for clinical use. The study was published on June 12, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Kindai University Hospital
Nihon Kohden
Sysmex
Abbott Diagnostics
Lion-Power
Beckman-Coulter
Different hematology analyzer models use various principles to measure the complete blood count (CBC) and leukocyte differential for routine tests in clinical laboratories. The accuracy performance of a hematology analyzer is evaluated using the manual differential leukocyte (Manual-Diff) on blood wedge film (Wedge-Diff) as the traditional reference method.
Clinical Laboratorians at the Kindai University Hospital (Osakasayama, Japan) selected for method comparison, 598 clinical samples and 46 healthy volunteer samples. All samples were collected in tubes containing K2-EDTA. The blood collection tubes, blood collection procedure, and mixing procedure were according to described methods. For method comparison between the three analyzers, 388 clinical samples were used. Blood films were stained with May-Giemsa.
The automated hematology analyzer Celltac G (Nihon Kohden, Tokyo, Japan) was designed to improve leukocyte differential performance. The two comparative hematology analyzers (CAAs) used were XN-9000 (Sysmex, Kobe, Japan) and CELL-DYN Sapphire (Abbott Diagnostics, Santa Clara, CA, USA). In manual differential, two kinds of automated slide makers were used: the Sysmex SP-10 for wedge technique and SPINNER-2000 (Lion-Power, Komatsu, Japan) for spinner technique. The immunophenotypic leukocyte differential reference method (FCM-Ref) was selected, and a flow cytometer Navios (Beckman-Coulter, Indianapolis, IN, USA) was used.
The investigators reported that the Celltac G showed sufficient comparability with the CAAs for each leukocyte differential counting value up to 40.87 × 109/L, and sufficient comparability with FCM-Ref for each leukocyte differential percentage at 0.4–78.5. The identification ratio of the FCM-Ref in CD45-positive cells was 99.7% (99.4% to 99.8%). Differences were found between FCM-Ref/Celltac G/XN-9000/Spinner-Diff and Wedge-Diff for monocytes and neutrophils. The appearance ratio of smudge cells on wedge and spinner film was 12.5% and 0.5%.
The authors concluded that the Celltac G hematology analyzer's leukocyte differential showed adequate accuracy compared with two comparative hematology analyzers, reference flow cytometry method, and two manual methods and was considered suitable for clinical use. The study was published on June 12, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Kindai University Hospital
Nihon Kohden
Sysmex
Abbott Diagnostics
Lion-Power
Beckman-Coulter
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







